Sfoglia per AUTORE
DANESI R
Collezione AO Ordine Mauriziano
Items : 3
Corrigendum: Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma. in Frontiers in oncology / Front Oncol. 2023 Aug 7;13:1232476. doi: 10.3389/fonc.2023.1232476. eCollection 2023.
2023
AO Ordine Mauriziano
AO Ordine Mauriziano
Zamagni C; Colombo N; Valabrega G; Savarese A; Sabbatini R; De Giorgi U; Gadducci A; Pignata S; Masi G; Danesi R; Locati LD; Lorusso D;
Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma. in Frontiers in oncology / Front Oncol. 2022 Sep 21;12:979519. doi: 10.3389/fonc.2022.979519. eCollection 2022.
2022
AO Ordine Mauriziano
AO Ordine Mauriziano
Danesi R; Locati LD; Zamagni C; Valabrega G; Savarese A; Sabbatini R; Gadducci A; Pignata S; De Giorgi U; Masi G; Colombo N; Lorusso D;
The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia. in Oncotarget / Oncotarget. 2017 Sep 30;8(50):88021-88033. doi: 10.18632/oncotarget.21406. eCollection 2017 Oct 20.
2017
AO Ordine Mauriziano
AO Ordine Mauriziano
Galimberti S; Bucelli C; Arrigoni E; Baratè C; Grassi S; Ricci F; Guerrini F; Ciabatti E; Fava C; D'Avolio A; Fontanelli G; Cambrin GR; Isidori A; Loscocco F; Caocci G; Greco M; Bocchia M; Aprile L; Gozzini A; Scappini B; Cattaneo D; Scortechini AR; La Nasa G; Bosi A; Leoni P; Danesi R; Saglio G; Visani G; Cortelezzi A; et alii...